|
|
rNDV-mOX40L |
|
Vaxjo ID |
254 |
|
Vaccine Adjuvant Name |
rNDV-mOX40L |
|
Alternative Names |
Recombinant Newcastle Disease Virus expressing murine OX40L. |
|
Adjuvant VO ID |
VO_0005741
|
|
Description |
A recombinant NDV engineered to express murine OX40 ligand (OX40L), enhancing anti-tumor immunity. Induces a Th1-biased immune response, increases CD8⁺ T cell infiltration, and reduces Tregs within tumors. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
To improve the anti-tumor immunity of NDV, the recombinant NDV expressing the murine OX40L (rNDV-mOX40L) was engineered |
|
Structure |
Recombinant virus based on NDV LaSota strain, genetically modified to include mOX40L gene. |
|
Preparation |
Constructed using reverse genetics; rNDV-mOX40L propagated in embryonated chicken eggs, purified, and titrated by TCID₅₀ assay. |
|
Dosage |
Intratumoral injection of 2×10⁶ TCID₅₀ per mouse, repeated every 2 days (total of 3 doses). |
|
Function |
To improve the anti-tumor immunity of NDV, the recombinant NDV expressing the murine OX40L (rNDV-mOX40L) was engineered. |
|
Safety |
Well-tolerated in mice. No systemic toxicity reported. NDV is nonpathogenic to humans. |
| References |
Tian et al., 2023: Tian L, Liu T, Jiang S, Cao Y, Kang K, Su H, Ren G, Wang Z, Xiao W, Li D. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy. Gene therapy. 2023; 30(1-2); 64-74. [PubMed: 34602608].
|
|
